KR102851057B1 - 질량 분석 키트 - Google Patents

질량 분석 키트

Info

Publication number
KR102851057B1
KR102851057B1 KR1020187027703A KR20187027703A KR102851057B1 KR 102851057 B1 KR102851057 B1 KR 102851057B1 KR 1020187027703 A KR1020187027703 A KR 1020187027703A KR 20187027703 A KR20187027703 A KR 20187027703A KR 102851057 B1 KR102851057 B1 KR 102851057B1
Authority
KR
South Korea
Prior art keywords
fragment
immunoglobulin
light chain
antibody
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187027703A
Other languages
English (en)
Korean (ko)
Other versions
KR20180132651A (ko
Inventor
데이비드 엘. 머레이
스테판 하딩
데이비드 알. 바니지
그레그 웰리스
존 밀스
제이미 애시비
Original Assignee
더 바인딩 사이트 그룹 리미티드
메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102851057(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 더 바인딩 사이트 그룹 리미티드, 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 filed Critical 더 바인딩 사이트 그룹 리미티드
Publication of KR20180132651A publication Critical patent/KR20180132651A/ko
Application granted granted Critical
Publication of KR102851057B1 publication Critical patent/KR102851057B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/34—Purifying; Cleaning
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/62—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Electrochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Sampling And Sample Adjustment (AREA)
KR1020187027703A 2016-02-25 2017-02-24 질량 분석 키트 Active KR102851057B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1603291.4A GB201603291D0 (en) 2016-02-25 2016-02-25 Antibodies
GB1603291.4 2016-02-25
US201662368606P 2016-07-29 2016-07-29
US62/368,606 2016-07-29
PCT/GB2017/050489 WO2017144900A1 (en) 2016-02-25 2017-02-24 Mass spectrometry kit

Publications (2)

Publication Number Publication Date
KR20180132651A KR20180132651A (ko) 2018-12-12
KR102851057B1 true KR102851057B1 (ko) 2025-08-28

Family

ID=55806928

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187027703A Active KR102851057B1 (ko) 2016-02-25 2017-02-24 질량 분석 키트

Country Status (10)

Country Link
US (1) US12461108B2 (https=)
EP (2) EP4123308A1 (https=)
JP (3) JP7246927B2 (https=)
KR (1) KR102851057B1 (https=)
CN (2) CN116148479A (https=)
AU (1) AU2017222399B2 (https=)
DK (1) DK3420361T3 (https=)
ES (1) ES2936783T3 (https=)
GB (1) GB201603291D0 (https=)
WO (1) WO2017144900A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201708262D0 (en) 2017-05-23 2017-07-05 Binding Site Group Ltd Assay for plasma cell associated disease
CA3126712A1 (en) * 2019-01-31 2020-08-06 Regeneron Pharmaceuticals, Inc. Native microfluidic ce-ms analysis of antibody charge heterogeneity
CN110009008B (zh) * 2019-03-18 2020-11-06 四川大学 基于提取的免疫固定电泳图特征对其进行自动分类的方法
GB201906599D0 (en) 2019-05-10 2019-06-26 Binding Site Group Ltd Mass spectrometry calibrator
WO2020229794A1 (en) 2019-05-10 2020-11-19 The Binding Site Group Limited Mass spectrometry calibrator
GB201915946D0 (en) 2019-11-01 2019-12-18 Binding Site Group Ltd Quantitation of immunoglobulins i n mass spectrometry
GB202007047D0 (en) * 2020-05-13 2020-06-24 Binding Site Group Ltd Mass spectrometry controls
GB202008887D0 (en) * 2020-06-11 2020-07-29 Binding Site Group Ltd A method of identifying or characterising an immune response in a subject
GB202016822D0 (en) 2020-10-23 2020-12-09 Binding Site Group Ltd Quantitation of immunoglobulins in mass spectrometry
CN113720900A (zh) * 2021-09-14 2021-11-30 首都医科大学附属北京朝阳医院 一种基于madli-tof ms技术检测血清中m蛋白的方法
CN114324557B (zh) * 2021-12-03 2024-05-10 融智生物科技（青岛）有限公司 一种基于MALDI-TOF MS的ζ-珠蛋白的检测方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015154052A1 (en) * 2014-04-04 2015-10-08 Mayo Foundation For Medical Education And Research Isotyping immunoglobulins using accurate molecular mass

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6290090A (en) 1989-08-29 1991-04-08 University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
WO1991006570A1 (en) * 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
EP1400536A1 (en) * 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ES2242189T3 (es) * 1994-05-13 2005-11-01 Miltenyi Biotec Gmbh Columna esteril y apirogena copulada a una proteina con miras a la fijacion y extraccion de sustancias dadas de la sangre.
JP2826965B2 (ja) * 1995-01-12 1998-11-18 オリエンタル酵母工業株式会社 免疫吸着体とその製造法
EP0862584B1 (en) 1995-11-03 2004-12-22 The Binding Site Limited Production of antibodies
US6207370B1 (en) * 1997-09-02 2001-03-27 Sequenom, Inc. Diagnostics based on mass spectrometric detection of translated target polypeptides
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
WO2005035721A2 (en) * 2003-10-08 2005-04-21 Ebioscience Native immunoglobulin binding reagents and methods for making and using same
GB0501741D0 (en) * 2005-01-27 2005-03-02 Binding Site The Ltd Antibody
CA2600844A1 (en) * 2005-03-14 2006-09-21 Medimmune, Inc. Macromolecules comprising a thioether cross-link
US7781178B2 (en) 2005-04-12 2010-08-24 Akira Matsumori Biomarker for diagnosing heart disease and the use thereof
US7893616B2 (en) * 2006-02-27 2011-02-22 Ohio State University Process to determine enzyme activity
US20100015652A1 (en) 2006-12-21 2010-01-21 Brian Walter Granda Antibody quantitation
RU2012118620A (ru) 2009-10-09 2013-11-20 Симфоген А/С Множественное количественное определение в смеси индивидуальных рекомбинантных белков посредством сигнатурных пептидов и масс-спектрометрии
GB201001946D0 (en) 2010-02-05 2010-03-24 Binding Site Group The Ltd Cancer prognostic assay
GB2478520A (en) 2010-03-02 2011-09-14 Binding Site Group Ltd Kidney prognostic assay
GB201117172D0 (en) 2011-10-05 2011-11-16 Binding Site Group The Ltd Diabetes
GB201121265D0 (en) 2011-12-12 2012-01-18 Binding Site Group The Ltd Assay
JP2015510877A (ja) * 2012-03-09 2015-04-13 ユーシーエル ビジネス パブリック リミテッド カンパニー 抗体の化学修飾
WO2014121031A1 (en) 2013-01-31 2014-08-07 Excelimmune, Inc. Characterization of antibody mixtures by mass spectrometry
WO2015131169A2 (en) * 2014-02-28 2015-09-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Personalized myeloma detection
EP3175242A4 (en) * 2014-07-29 2017-12-27 Mayo Foundation for Medical Education and Research Quantifying monoclonal antibody therapeutics by lc-ms/ms
PT3209767T (pt) * 2014-10-21 2020-11-09 Gennova Biopharmaceuticals Ltd Um novo processo de purificação para isolamento e produção comercial de tnk-tpa recombinante (tenecteplase)
CN108026164A (zh) 2015-09-24 2018-05-11 梅约医学教育与研究基金会 通过质谱鉴定免疫球蛋白游离轻链
GB201708262D0 (en) * 2017-05-23 2017-07-05 Binding Site Group Ltd Assay for plasma cell associated disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015154052A1 (en) * 2014-04-04 2015-10-08 Mayo Foundation For Medical Education And Research Isotyping immunoglobulins using accurate molecular mass

Also Published As

Publication number Publication date
EP3420361B1 (en) 2023-01-04
JP2022069446A (ja) 2022-05-11
KR20180132651A (ko) 2018-12-12
JP7541070B2 (ja) 2024-08-27
EP4123308A1 (en) 2023-01-25
CA3015296A1 (en) 2017-08-31
WO2017144900A1 (en) 2017-08-31
CN116148479A (zh) 2023-05-23
ES2936783T3 (es) 2023-03-22
DK3420361T3 (da) 2023-01-23
EP3420361A1 (en) 2019-01-02
US20190094239A1 (en) 2019-03-28
AU2017222399B2 (en) 2024-03-14
AU2017222399A1 (en) 2018-08-30
US12461108B2 (en) 2025-11-04
GB201603291D0 (en) 2016-04-13
CN108885218A (zh) 2018-11-23
JP7541045B2 (ja) 2024-08-27
BR112018067435A2 (pt) 2019-01-02
JP7246927B2 (ja) 2023-03-28
JP2023033281A (ja) 2023-03-10
JP2019509483A (ja) 2019-04-04

Similar Documents

Publication Publication Date Title
JP7541070B2 (ja) 質量分析キット
US20230080943A1 (en) Assay for plasma cell associated disease
US20230391851A1 (en) Antibodies
Teixeira et al. Presence of N‐glycosylated transthyretin in plasma of V30M carriers in familial amyloidotic polyneuropathy: an escape from ERAD
CA3015296C (en) Mass spectrometry kit
HK40087264A (en) Mass spectrometry kit
BR112018067435B1 (pt) Método para purificar ou caracterizar uma imunoglobulina, método para quantificar uma quantidade de um analito de indivíduo ou um fragmento de um analito em uma amostra do indivíduo, método de preparação de uma amostra para análise de espectrometria de massa, método para diagnosticar ou prognosticar uma doença relacionada a células b ou outra doença relacionada com a imunidade, e kits de ensaio
Prądzińska et al. Isolation and characterization of autoantibodies against human cystatin C
HK40081916A (en) Assay for plasma cell associated disease
RU2281510C1 (ru) АНТИТЕЛА, СПЕЦИФИЧЕСКИ РЕАГИРУЮЩИЕ С ПРИОННЫМ ПРОТЕИНОМ PrP ИЛИ ЕГО ФРАГМЕНТОМ, И ИХ ПРИМЕНЕНИЕ
Wiegand Molecular epitope and affinity determination of protein-protein interactions by a combination of biosensor and mass spectrometric methods
JP2010054245A (ja) 生体内緊張状態の緩和・誘導抑制効果の評価方法及び評価用キット、並びに、物質のスクリーニング方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)